Entwodiksyon: Itilizasyon teknoloji enprime 3D nan fabrikasyon dwòg gen gwo potansyèl pou devlopman paske li ka jisteman kontwole estrikti pò nan tablèt la ak Customize dwòg selon bezwen aktyèl pasyan yo. Yon domèn rechèch ak eksperimantasyon.
△ 3D printed tablets can be dissolved quickly, the picture comes from Aprecia
Nan dat 13 fevriye 2022, Antatik Bear a te enfòme ke chèchè nan University of Queensland (UG) te lanse yon papye sou wòl nan enprime 3D nan bay medikaman pèsonalize pou pasyan nan lavni, epi pibliye yon papye ki gen rapò.
Dapre Liam Krueger, yon famasyen, yon etidyan PhD nan University of Queensland ak prensipal otè papye a, teknoloji enprime 3D ase pou pèmèt enprime egzat dòz espesyalize sou sit-nan lopital ak famasi nan kèk ane kap vini yo. . Atravè rechèch sa a, chèchè yo espere akselere devlopman nan medikaman enprime 3D nan Ostrali ak aletranje.
Kruger said: "3D printing technology is often used in other medical settings such as dentistry, orthopaedic implants, however in the pharmaceutical field, the utilization of 3D printing technology is lagging behind. Through this research, we hope to promote 3D printing The development of pharmaceutical technology, this is an opportunity for the future of the Australian pharmaceutical industry."
△Spritam is the world's first FDA-approved 3D-printed drug, marketed by Aprecia Pharmaceuticals. Used to treat seizures, 3D-printed pills have higher porosity than traditionally manufactured pills, which means they dissolve and act faster in the body. Image via Aprecia
Avans nan Enpresyon 3D nan famasetik
Yo kwè ke fabrikasyon aditif yo ofri anpil avantaj pou devlopman klinik pharmaceutique, tankou pèsonalize tretman ki baze sou bezwen pasyan yo, akselere tan livrezon medikaman yo, ak pèmèt tretman sou demann, men tranzisyon 3D- teknoloji enprime dwòg soti nan laboratwa a nan klinik la se toujou nan anfans li. kòmanse-etap moute.
△The application of 3D printing in the pharmaceutical industry, the picture comes from FabRx
There have been some notable developments in this area, though, notably Aprecia, which won the first FDA approval for a 3D-printed drug back in 2015. Aprecia's drug Spritam has been approved to treat epilepsy, and they have since continued to scale up production through a partnership with RD company Battelle.
Aprecia te devlope medikaman pèsonalize pou trete maladi metabolik ki ra nan timoun yo atravè yon platfòm fabrikasyon dwòg fleksib, e li te kreye grenn enprime 3D ak bray ak modèl lalin pou ede pasyan ki gen pwoblèm vizyèl pran medikaman yo.
Anplis de sa, konpayi pharmaceutique mondyal Merck te lanse yon pwojè ansanm ak AMCM, yon konpayi EOS, pou devlope ak pwodwi 3D enprime tablèt pharmaceutique nan 2020, premye pou esè klinik ak pita pou pwodiksyon komèsyal yo.
Nan Lachin, gen tou trè kèk konpayi angaje nan rechèch dwòg enprime 3D. Yon sèl ki pi reprezantan se Nanjing Triassic, ki te etabli an 2015. Yo pran angajman pou konstwi yon nouvo platfòm teknoloji dwòg enprime 3D. Devlopman dijital, nan teknoloji a propriétaires nan tout chèn nan pwodiksyon entelijan. Kounye a, kòm premye konpayi pharmaceutique Chinwa a chwazi pou pwojè teknoloji émergentes nan US FDA, Triassic ap patisipe nan fòmilasyon estanda endistri pharmaceutique US Pharmacopeia enprime 3D.
Done yo montre ke Triassic okipe plis pase 1/5 nan kantite aplikasyon patant nan jaden an dwòg enprime mondyal 3D, epi li se sou yo bati yon liy pwodiksyon kontinyèl ak entèlijan 3D enprime dwòg ak yon kapasite pwodiksyon anyèl nan 50 milyon moso.
Èske grenn enprime 3D lavni medikaman?
University of Queensland te fè dènye rechèch nan domèn medikaman enprime 3D, ki montre ke kounye a teknoloji a ase sofistike pou yo deplwaye nan lopital ak famasi alavni.
"3D printing technology can tailor a drug to a patient to ensure it has the exact dose or combination for a specific need," Krueger said. "Through 3D printing, we can combine five pills into one and even change the size of the pills. , shape, color, taste or texture."
Malgre avantaj klè nan medikaman enprime 3D, toujou gen kèk defi ki bezwen adrese pou adopsyon toupatou nan anviwònman medikal.
Youn nan defi yo se tan enprime. Konvansyonèl, li pran apeprè 3 minit pou enprime yon gwosè estanda 10x3mm tablèt, ak apeprè 45 minit pou yon pakèt 28 tablèt. Sa a twò lontan pou yon medikaman ki vle deplwaye sou-demann nan yon klinik, epi ki bezwen vin pi kout pou yo ka pratik nan mond reyèl la.
Sepandan, ko-otè papye a, Pwofesè Asosye Amirali Popat nan University of Queensland kwè enprime 3D ta ka diminye kantite medikaman yon pasyan dwe pran.
"Polypharmacy is the use of five or more drugs at the same time, and about two-thirds of 75-year-old Australians are in such treatment," he said. "The real benefit of 3D-printed pills lies with the consumer or the patient, although There's still some way to go before it happens, but it's a very exciting development."
The research is the beginning of the University of Queensland's research on the feasibility of using 3D printing technology for personalised medicine in the real world, and the data collected so far is promising, the researchers said.
Co-author Chris Freeman (National President of the Pharmaceutical Association of Australia) said: "In the future, 3D printing could help people who need to take multiple medicines to take the right medicine at the right time and in the right dose."
More information about this study can be found in the paper titled "3D printing: Potential clinical applications for personalised solid dosemedications", published in the Medical Journal of Australia. Co-authors of the study are L. Krueger, J. Miles, K. Steadman, T. Kumeria, C. Freeman and A. Popat.
